OsteoMiR -- a novel disease-modifying drug for the treatment of osteoarthritis.

骨关节炎(OA)是老年人残疾的主要原因，每8人中就有1人受到影响。约75%的OA患者报告持续疼痛，约30%的人因此而放弃工作或减少工作时间。美国和欧洲的办公自动化成本估计为GDP的1%-2.5%。目前，还没有治疗骨关节炎的药物(DMOAD)。软骨丢失被认为是骨关节炎症状的主要原因，因此，限制或逆转这种损害的治疗可能会减少症状并使患者受益。铜锣湾治疗公司正在开发一种独特的治疗方法，这种治疗方法专门针对推动骨性关节炎发展的细胞途径，这些细胞途径可以阻止疾病的发展，恢复功能和减轻疼痛。

Osteoarthritis (OA) is the leading cause of disability in older adults with 1 in 8 being affected. Around 75% of people with OA report constant pain, with approximately 30% giving up work or reducing the number of hours they work due to the condition. The cost of OA in the USA and Europe has been estimated at 1-2.5% of GDP. Currently, there are no Disease-Modifying OA Drugs (DMOAD). Loss of cartilage is believed to be a major cause of osteoarthritis symptoms and therefore, therapies that limit or reverse this damage are likely to reduce symptoms and benefit patients. Causeway Therapeutics is developing a treatment that uniquely targets the cellular pathways that drive the development of OA stopping disease progression, restoring function and reducing pain.